←Back to Expert Scholars
Translational Medicine / 转化医学TCR-T Cell Therapy, CTA Targets
Patrick Hwu
MD
🏢Moffitt Cancer Center🌐USA
President and CEO
110
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Patrick Hwu is a pioneer of adoptive T cell therapy including TCR-engineered T cells targeting cancer-testis antigens such as MAGE-A3. He led early TCR-T trials at the NCI and now directs Moffitt Cancer Center's strategic cell therapy programs.
Share:
🧪Research Fields 研究领域
TCR-T therapy
adoptive cell therapy
MAGE-A3 TCR
tumor antigen targeting
melanoma immunotherapy
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Patrick Hwu 的研究动态
Follow Patrick Hwu's research updates
留下邮箱，当我们发布与 Patrick Hwu（Moffitt Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment